Rapport Therapeutics, Inc. (RAPP) stock
Close on Nov 11, 2026Market cap $1.30BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.30B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.31
- Dividend yield
- –
- Free cash flow yield
- -9.35%
Fundamentals
- Net income
- -$150.47M
- EPS, diluted
- -$3.17
- Free cash flow
- -$121.18M
- Book value per share
- $8.19
- Diluted shares
- 48M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $25.96
- Open
- $26.06
- Day's range
- $25.77 – $27.10
- Volume
- 631,810
- Average volume (20 days)
- 1,627,739
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.77
- 52-week range
- $22.06 – $52.93
- RSI (14 days)
- 47.1
- Volatility (1 year)
- 62.1%
- Relative volume
- 0.98×
- WACC
- 13.7%
On 2 of our idea lists: Insider cluster buys, Insiders buying the dip
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RAPP | S&P 500 | Difference | RAPP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.8% | -2.4% | −9.4 pts | ||
| 3 months | -44.7% | -1.2% | −43.5 pts | ||
| Year to date | -10.9% | +12.3% | −23.2 pts | ||
| 1 year | +6.0% | +12.4% | −6.5 pts | ||
| 3 years | +1701.3% | +78.8% | +1622.5 pts | +162.1% | +21.4% |
| 5 years | +1701.3% | +75.2% | +1626.2 pts | +78.3% | +11.9% |
| 10 years | +1701.3% | +311.1% | +1390.2 pts | +33.5% | +15.2% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rapport Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Update
About Rapport Therapeutics
Pharmaceutical Preparations
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule precision medicines for patients with neurological and psychiatric disorders. The company utilizes a receptor-associated protein platform to target specific neuronal receptor assemblies. Its lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator in development for drug-resistant focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. In addition, the firm advances discovery-stage nicotinic acetylcholine receptor programs, including RAP-641 for chronic pain and migraine, alongside therapies for hearing and vestibular disorders. Its patient population comprises individuals affected by serious central nervous system and sensory conditions.
Company profile, executives and historyRapport Therapeutics stock: common questions
What is Rapport Therapeutics's stock price?
RAPP closed at $27.02 on Nov 11, 2026, up 4.08% on the day. Over the past 52 weeks it traded between $22.06 and $52.93.
What is Rapport Therapeutics's market cap?
Rapport Therapeutics was worth $1.30B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RAPP's P/E ratio?
Rapport Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.17), so it has no meaningful P/E ratio.
Does Rapport Therapeutics pay a dividend?
No. Rapport Therapeutics has not paid a cash dividend over the last twelve months.
When does Rapport Therapeutics report earnings next?
Rapport Therapeutics is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RAPP stock performed over the past year?
Including dividends, RAPP returned +6.0% over the past year, against +12.4% for the S&P 500.
How many RAPP shares are sold short?
4M shares were sold short at the latest FINRA report, 16.92% of the float, or 1.8 days of average trading volume.
Who are Rapport Therapeutics's competitors?
Companies most similar to Rapport Therapeutics by business, industry and size include NERV, MPLT, OVID, CAMP, XENE.
See a number that looks wrong?